Shanghai Zerun Biotech Co., Ltd. (Zerun Biotech) was founded in 2003 and is located in Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai. Focusing on the research, development and industrialization of new recombinant human vaccines, Zerun Biotech is undertaking several national new drug development projects and has been recognized as National Hi-Tech Enterprise. At the end of 2012, Zerun Biotech became a holding subsidiary of Yunnan Walvax Biotechnology Co., Ltd., a listed vaccine company on Shenzhen Growth Enterprise Market. Adhering to the belief of “Life is priceless and technology is limitless” and the purpose of “Help everyone live a healthy life”, the company is dedicated to becoming the pride domestically and the pioneer globally in the vaccine industry.
Shanghai Zerun Biotechnology Co., Ltd. is dedicated to the development of new recombinant vaccines. Zerun Biotech possesses platforms for Preparation of Virus-Like Particles, Recombinant Protein Expression and Innovative Adjuvant Evaluation. Based on yeast expression system, the company has developed bivalent and nine-valent preventive Human Papillomavirus Vaccine (HPV vaccine), and other vaccines, among which the bivalent HPV vaccine has been approved for marketing in China on March 22, 2022 and the 9-valent HPV vaccine has entered Phase III clinical trials. Grounded in CHO cell expression system, Zerun Biotech has progressed in two SARS-CoV-2 vaccines and Varicella-Zoster Virus vaccine, of which the SARS-CoV-2 prototype vaccine has completed Phase II clinical trials, and the SARS-CoV-2 variant vaccine has completed Phase I clinical trials at home and abroad.
To achieve its product development goal, Zerun Biotech established its first manufacturing facility in 2016 for its HPV vaccine production. The site named Yuxi Zerun Biotechnology Co., Ltd. (“Yuxi Zerun”) and located in Yuxi City, Yunnan Province, is an innovation-driven biopharmaceutical company focusing on the industrialization, production and operation of new recombinant vaccines for human use. With the support from Bill & Melinda Gates Foundation, Yuxi premise was designed and constructed to meet both current Chinese and WHO prequalification (WHO-PQ) requirements. The premise is a modern four-story building covering an area of over 4,000 square meters (~40,000 sf) and the premise area is about 20,000 square meters (~200,000 sf), with a capacity producing an initial 15 million doses of bivalent HPV vaccine a year. The state-of-art premise is furnished with top international brand manufacturing equipment to ensure production continuity and process stability. In early 2018, Yuxi Zerun was granted a “Drug Manufacturing License” by the provincial branch of CFDA (now the National Medical Products Administration), signifying the readiness of the plant for production.
Zerun is a fast growing biotech company in China. With high expectation of continuous expending in next 5 years, Zerun is currently strengthening its R&D, production and management teams preparing for a rapid increase in operation in near and long term. We sincerely invite qualified professionals from aboard and domestic to join us for building an outstanding biotech industry platform aimed at both domestic and international market.
If you are interested in working for the company, please send your CV to us and feel free to contact us at firstname.lastname@example.org.
Monday to Friday 9:00-18:00